Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin?

Nature Clinical Practice Nephrology

Volumn 2, Issue 3, 2006, Pages 134-135

  Sayegh, Mohamed H ^a,b   Chandraker, Anil ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute rejection; Belatacept; Ciclosporin; Renal transplantation

Indexed keywords

BASILIXIMAB; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG;

CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DIABETES MELLITUS; DONOR; DRUG INDUCED CANCER; EUROPE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; NOTE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; UNITED STATES; URINARY TRACT INFECTION;

EID: 33644826737     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0125     Document Type: Note

References (4)

1. Sayegh MH and Turka LA (1998) The role of T-cell costimulatory activation pathways in transplant rejection N Engl J Med 338: 1813-1821
2. Larsen CP et al. (2005) Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5: 443-453
3. Tran HT et al. (2000) Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 11: 1903-1909
4. Kreis H et al. (2004) Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15: 809-817